Medsky Topics www.dailymaverick.co.za
Ozempic, Wegovy and the R33bn bill that is SA's obesity time bomb | Daily Maverick
A Medsky Topics feed composed of posts covering recent news related to GLP-1 Agonists such as Semaglutide (Ozempic, Wegovy, Rybelsus), Liraglutide (Victoza), and Tirzepatide (Zepbound, Mounjaro) Powered by @medsky.social
Feed on BlueskyFeeds Stats
- đ Liked by 15 users
- đ Updated 23 days ago
- âïž Provider graze.social
- đ In the last 30 days, there was 1 post about this feed. This post got a total of 6 likes and had 1 repost.
GLP-1 Agonists Likes over time
Like count prediction
The feed GLP-1 Agonists has not gained any likes in the last month.
Feed Preview for GLP-1 Agonists
In New Dementia Trials, Ozempicâs âMiracle Drugâ Image Takes a Hit www.nytimes.com/2025/12/1âŠ.
www.nytimes.com
In New Dementia Trials, Ozempicâs âMiracle Drugâ Image Takes a Hit
0
0
1
Heart, kidney, disease may be one ailment
These three disorders could really be âCKM syndrome,â which can be treated with drugs like Ozempic
www.scientificamerican.coâŠ.
www.scientificamerican.com
Heart and Kidney Diseases, plus Type 2 Diabetes, May Be One New Syndrome Treatable with New Drugs
These three disorders could really be âCKM syndrome,â which can be treated with drugs like Ozempic
0
2
5
Lawsuits claiming Ozempic, other GLP-1s led to blindness become second mass litigation over the drugs reut.rs/3N2CHXp
reut.rs
Lawsuits claiming Ozempic, other GLP-1s led to blindness become second mass litigation over the drugs
A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly alleging patients lost some or all of their eyesight while taking the companies' blockbuster weight loss drugs before a judge in Pennsylvania.
7
23
40
Two of the largest clinical trials of their kind have doused hopes that a diabetes and weight loss âwonder drugâ might also work its magic on Alzheimerâs.
www.sciencenews.org/articâŠ
www.sciencenews.org
GLP-1 drugs failed to slow Alzheimerâs in two big clinical trials
Tantalizing results from small trials and anecdotes raised hopes that drugs like Ozempic could help. Despite setbacks, researchers arenât giving up yet.
0
3
6
Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma compared with GLP-1 drugs among patients with type 2 diabetes, a large retrospective cohort study suggested.
www.medpagetoday.com/ophtâŠ
0
0
3
Obesity is a big driver of healthcare spending in South Africa, yet most medical schemes still limit cover for effective treatments. The gap between the scale of the problem and the funding response is widening, with long-term consequences for patients, insurers and the public purse.
www.dailymaverick.co.za
Ozempic, Wegovy and the R33bn bill that is SA's obesity time bomb | Daily Maverick
1
0
1
Since 2023, the state has paid for Medicaid patientsâ weight-loss treatment with these drugs, known as GLP-1s.
www.spotlightpa.org/news/âŠ
www.spotlightpa.org
Pennsylvania restricts Medicaid coverage for GLPâ1 drugs
Starting Jan.âŻ1, 2026, Pennsylvania will limit GLPâ1 weightâloss drugs under Medicaid â threatening access for thousands of lowâincome patients.
0
0
1
Since 2023, the state has paid for Medicaid patientsâ weight-loss treatment with these drugs, known as GLP-1s.
www.spotlightpa.org/news/âŠ
www.spotlightpa.org
Pennsylvania restricts Medicaid coverage for GLPâ1 drugs
Starting Jan.âŻ1, 2026, Pennsylvania will limit GLPâ1 weightâloss drugs under Medicaid â threatening access for thousands of lowâincome patients.
0
1
3
Last in the trilogy!
Bench to Bedside: From Results to Patient Care
Topic: GLP-1 RAs and HFpEF â Which patients should receive them?
Monday, 15 December | 18:00â19:00 CET.
Register now â free for everyoneđ ow.ly/63sh50XJtqH
Missed Webinar 2? Watch on demandđ ow.ly/Nk0e50XJtqI
0
0
0
GLP-1 receptor agonists were tied to a lower risk of developing epilepsy in adults with type 2 diabetes, a large U.S. study showed.
Epilepsy is an underrecognized comorbidity in people with type 2 diabetes, the researchers noted.
www.medpagetoday.com/neurâŠ
1
0
1
ICYMI: New content online: Advances in incretin-based drug discovery in 2025
www.nature.com
Advances in incretin-based drug discovery in 2025
Nature Reviews Endocrinology, Published online: 12 December 2025; doi:10.1038/s41574-025-01219-4The efficacy of anti-obesity drugs that use glucagon-like peptide 1 receptor agonism and glucose-dependent insulinotropic polypeptide agonism raises critical questions about how next-generation drugs might offer increased metabolic benefits. In 2025, new research into incretin-based treatments has brought us closer to answering these questions.
0
0
0
Pharmaceutical bosses have issued a stark warning about medicines such as Mounjaro sold online without safety controls as gangs branch out from hard drugs
www.thetimes.com
Criminals selling dangerous weight-loss jabs on social media and in gyms
Pharmaceutical bosses have issued a stark warning about medicines such as Mounjaro sold online without safety controls as gangs branch out from hard drugs
2
5
6
[email protected] published a guideline in JAMA on the use and indications of #GLP-1 therapies for the management of #obesity in adults. The guideline offers two conditional recommendations to inform clinical practice and health policy.
Read the guideline: ja.ma/4oNCLHN
1
3
17
#Throwback đ§Ș
VIEWPOINT | A salute to innovation: exenatide in diabetes and obesity drug development at Amylin Pharmaceuticals
JL Trevaskis et al.
bit.ly
A salute to innovation: exenatide in diabetes and obesity drug development at Amylin Pharmaceuticals - Nature Metabolism
The glucagon-like peptide 1 receptor agonist (GLP-1RA) class of medicines has emerged as transformative for the treatment of diabetes, obesity and other diseases. On the twentieth anniversary of the approval of exenatide (Byetta), three former employees of Amylin Pharmaceuticals acknowledge the contributions of some of the individuals and the innovation responsible for delivering the first approved GLP-1RA â the forerunner to the modern blockbuster drugs.
0
1
7
Incretin hormonesâglucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)âact as a critical link connecting #digestion, #metabolism, & #cardiovascular function, supporting physiological adaptations to nutrient intake thelancet.com/journals/lan...
#incretins
#MedSky #EndoSky
0
1
4
Alzheimer's drug hunt learns from cancer fight's multi-target playbook reut.rs/48LBHy9
reut.rs
Alzheimer's drug hunt learns from cancer fight's multi-target playbook
Alzheimer's trials testing Novo Nordiskâs blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to approaching the brain-wasting disease as a system of complex pathways, much the way the field of cancer therapeutics has been transformed in recent years.
0
8
23
"One small molecule for man, one giant leap for mankind with obesity"
sciencedirect.com/scienceâŠ.
But the very high amounts of drug in pills relative to injectable peptides, due to such poor bioavailability, means we need to be watchful for new side effects when these pills get widely used
sciencedirect.com
One small molecule for man, one giant leap for mankind with obesity
The ATTAIN-1 trial launches a new era in obesity care. Orforglipron, the first oral small-molecule GLP-1 receptor agonist to complete a phase 3 clinicâŠ
2
20
81
New content online: Advances in incretin-based drug discovery in 2025
www.nature.com
Advances in incretin-based drug discovery in 2025
Nature Reviews Endocrinology, Published online: 12 December 2025; doi:10.1038/s41574-025-01219-4The efficacy of anti-obesity drugs that use glucagon-like peptide 1 receptor agonism and glucose-dependent insulinotropic polypeptide agonism raises critical questions about how next-generation drugs might offer increased metabolic benefits. In 2025, new research into incretin-based treatments has brought us closer to answering these questions.
0
0
1
Ophthopedia Update: Bariatric Surgery May Outperform GLP-1 RAs in Longer-Term Weight Loss Benefits: In patients with obesity, a retrospective study found greater weight loss and lower costs over 2 years after metabolic bariatric surgery than with glucagon-like peptide-1⊠#Ophthalmology #News
dlvr.it
Bariatric Surgery May Outperform GLP-1 RAs in Longer-Term Weight Loss Benefits
In patients with obesity, a retrospective study found greater weight loss and lower costs over 2 years after metabolic bariatric surgery than with glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment.
0
0
0
Last in the trilogy! Bench to Bedside: From Results to Patient Care
Topic: GLP-1 RAs and HFpEF â Which patients should receive them?
Monday, 15 December from 18:00 to 19:00 CET.
Register now â free for everyone: ow.ly/F9Ea50XIoAO
Missed Webinar 2? Watch on demand: ow.ly/mZlP50XIoAN
0
0
0
Ozempic launches in India at $24 a week as Novo targets booming diabetes market reut.rs/48QpEjl
reut.rs
Ozempic launches in India at $24 a week as Novo targets booming diabetes market
Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week and targeting a booming diabetes and obesity market expected to power industry growth this decade.
1
5
13
Ophthopedia Update: GLP-1s may reduce risk for cataracts, dry AMD: GLP-1 receptor agonists are not associated with increased risks for dry age-related macular degeneration or cataract development, according to two recently published studies.
The data instead showed⊠#ophthalmology #eye #eyenews
dlvr.it
GLP-1s may reduce risk for cataracts, dry AMD
GLP-1 receptor agonists are not associated with increased risks for dry age-related macular degeneration or cataract development, according to two recently published studies. The data instead showed significantly reduced risk for cataracts, as well as lower risk for dry AMD, linked with the use of GLP-1s, according to Abhimanyu Ahuja, MD, an ophthalmology resident at the Oregon Health & Science University Casey Eye Institute, and colleagues. âOther studies have demonstrated that these medications have anti-inflammatory and neuroprotective properties,â Ahuja told Healio. âWe
0
0
0
29% weight loss, 71 pounds!
That what the triple receptor GLP-1 drug retatrutide achieved in a placebo-controlled trial
Plus 3-fold complete relief of knee osteoarthritis pain
www.nytimes.com/2025/12/1âŠ.
www.nytimes.com
Major Weight Loss and Knee-Pain Relief Seen With New Eli Lilly Drug
9
37
122